Pfizer scored an accelerated approval Friday to bring its BRAF inhibitor to first-line colorectal cancer patients.

Applied Therapeutics CEO Shendelman exits; CFO Funtleyder becomes interim CEO after FDA rejects govorestat. Company withdraws ...

Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...

House Speaker Johnson and GOP push for narrow spending bill without healthcare reforms as midnight shutdown deadline looms; ...

Aadi Bioscience sells cancer drug Fyarro to Kaken Pharmaceutical for $100M, licenses three ADCs from WuXi Biologics and ...

→ Yu­ki Abe will step in to re­place the late Toshi­nori Agat­suma on Jan. 1 as head of … Get free access to a limited number ...

Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.

FDA approves Ionis' olezarsen as first treatment for familial chylomicronemia syndrome. Arrowhead's plozasiran pending FDA ...

The FDA rejected Zealand Pharma’s short bowel syndrome drug, and asked the company to run another trial before it reconsiders ...

Rhythm Pharmaceuticals received FDA approval to market its genetic obesity drug Imcivree for children as young as 2 years old ...

Syncromune, a biotech startup working on combination immunotherapies, has put together a $100 million Series A, the company ...

The Institute for Clinical and Economic Review said major insurers’ drug coverage policies generally do align with the ...